Maribavir (livtencity)
Ended Awarded Last action
- Contract number
- 36C25226N0265
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624
- Awarding agency
-
Veterans Integrated Service Network 12
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $28,112
Award facts
- Contract value 100% obligated
- $28,111.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lexington, MA 02421, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $4,586 | |
| Supplemental Agreement for work within scope | $4,785 | |
| Supplemental Agreement for work within scope | $9,371 | |
| Original award | $9,371 |
About this award
Takeda Pharmaceuticals America Inc. received a delivery order valued at $28,111.59 from Veterans Integrated Service Network 12 for MARIBAVIR (LIVTENCITY), an antiviral pharmaceutical for transplant-related infections. This firm fixed-price delivery order, awarded on February 4, 2026, with an ultimate completion date of April 3, 2026, represents a child contract under the General Services Administration Pharmaceuticals and Drugs Schedule (FSS-61-IB). The award was not designated with a set-aside and will be performed in Lexington, Massachusetts, where Takeda maintains its headquarters. As a specialist in biopharmaceutical products serving federal healthcare entities, Takeda's work supports the Department of Veterans Affairs' critical mission of providing advanced medical treatments to veteran and federal beneficiary populations.
This delivery order derives from Takeda's comprehensive single-award Blanket Purchase Agreement with the Department of Veterans Affairs National Acquisition Center, valued at $131,039,520.00 and effective through July 14, 2026. The BPA structure streamlines federal pharmaceutical procurement across nine specialized products addressing complex conditions including rare genetic disorders, immune deficiencies, and transplant-related complications. This delivery order mechanism enables Veterans Integrated Service Networks to rapidly procure MARIBAVIR without conducting individual competitive procurements, reducing administrative burden while maintaining established pricing terms aligned with federal healthcare delivery requirements.
Quick answers
Who was awarded contract 36C25226N0265?
36C25226N0265 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 12 (Veterans Health Administration) on February 4, 2026.
How much is contract 36C25226N0265 worth?
The government has obligated $28,112 on 36C25226N0265.
Is contract 36C25226N0265 an order under another contract?
Yes. 36C25226N0265 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25226N0265 competed?
The extent of competition for 36C25226N0265 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award